Drugs / pegylated interpheron alpha-2a
last change Jun 2017 re-read 2 minutes ago

pegylated interpheron alpha-2a

Developed for
systemic mastocytosis
Investigated by
Hospital Virgen de la Salud

Trials 1 · a red edge is where a trial was stopped

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT01602939 May 2012 → Feb 2017 systemic mastocytosis Hospital Virgen de la Salud Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as pegylated interpheron alpha-2a ClinicalTrials.gov intervention name — accepted as the source's own label NCT01602939
Route Subcutaneous “Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months.” NCT01602939